|
|||||
|
|
A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes |
|
| Authors: | Yehoshua Gozes Douglas E. Brenneman Mati Fridkin Richard Asofsky Illana Gozes |
| Affiliation: | aLaboratory of Immunology National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, U.S.A. bIsrael Institute for Biological Research, Ness Ziona, Israel cUnit on Neurochemistry Laboratory of Developmental Neurobiology National Institute of Child Health and Human Development NIH, Bethesda, MD 20892, U.S.A. dDepartment of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel eDepartment of Chemical Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel |
| Abstract: | Vasoactive intestinal peptide (VIP) is a neuropeptide which also interacts with cells of the immune system. The paucity of specific VIP receptor antagonists has hampered studies of possible receptor heterogeneity and of VIP function. To aid in achieving these goals, a new VIP antagonist, a hybrid between neurotensin and VIP, has been synthesized. This peptide interacted with VIP receptors on spinal cord cells with an affinity 10-fold greater than VIP itself. In contrast, 1000-fold higher concentrations of the antagonist were required to displace labeled VIP from its receptor on lymphoid cells as compared to VIP itself, suggesting VIP receptor heterogeneity between immune and spinal cord cells. |
| Keywords: | Vasoactive intestinal peptide Spinal cord cell culture Lymphocyte Vasoactive intestinal receptor Vasoactive intestinal peptide receptor antagonist |
| 本文献已被 ScienceDirect 等数据库收录！ | |